Bing Liang Ph.D.

Dr. Bing Liang represents biotechnological and pharmaceutical companies on the procurement and protection of intellectual property, particularly in the areas of biologics and diagnostics. Bing drives global intellectual property strategies for high-value innovative medicines, with a proven track record of success creating strategic patent assets covering some of the world's most valuable life-saving medicines, including CARVYKTI^®, PALYNZIQ^®, PADCEV^™, VENCLEXTA^®, NUPLAZID^®, POMALYST^®, REVLIMID^®, and OTEZLA^®.

She prepares and prosecutes patent applications in a variety of technologies including antibody therapeutics, immuno-oncology therapeutics, cell and gene therapies, genome editing, antisense therapeutics, enzyme replacement therapies, stem cells, and genome sequencing.

Bing advises patentability, validity, infringement, and freedom-to-operate issues and performs due diligence evaluations of patent portfolios in connection with venture capital and private equity financings, collaborations, and/or partnering deals. She is experienced in licensing agreements.

Her practice also includes various post-grant proceedings before the Patent Trial and Appeal Board (PTAB), including inter partes reviews (IPRs).

Her representative clients include AbbVie, Merck, BioMarin Pharmaceutical, Bristol Myers Squibb (Celgene), Legend Biotech, and Astellas, as well as other start-up companies, established companies, academic institutions, and investment firms.

Prior to practicing law, Bing obtained her Ph.D. in biomedical sciences from Mount Sinai School of Medicine of New York University, where her research focused on chromatin remodeling and its functions in maintaining genome integrity. During this time she discovered important roles of chromatin remodeling complexes in DNA damage repair and telomere length maintenance. Bing has extensive technical experience in biochemistry, molecular biology, genetics, immunology, and cell biology.